ASN applauds the U.S. Food and Drug Administration for amending the emergency use authorizations for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, including kidney transplant recipients.
In a letter to HRSA, ASN emphasized the need for separating the technology portion of the OPTN contract as a stand-alone contract, requiring OPTN contractors to have complete and accurate data, and the enforcement of separate governance boards.
In a recent letter to the Centers for Medicare & Medicaid Services (CMS), ASN submitted comments on a proposed rule concerning the End-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and End-Stage Renal Disease Treatment Choices (ETC) Model.
During Kidney Week, STARS participants attend poster sessions, “Meet the Expert” panel discussions, and networking opportunities with nephrology leaders. STARS participants are grouped by special interest and paired with mentors who offer guidance during the event.
Prediction models can process factors that modify patient risk and transform them into a single probabilistic prediction that can be used to help patients and doctors make good choices and fairly allocate care.